Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 8215 results

  1. Ianalumab for treating active Sjogren's syndrome [ID6634]

    In development Reference number: GID-TA11836 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    In development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gambling

    Awaiting development Reference number: GID-QS10099 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Secondary care management of malignant hypertension

    Awaiting development Reference number: GID-QS10107 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Sleep disordered breathing

    Awaiting development Reference number: GID-QS10096 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Readmission to ICU within 48hrs

    Awaiting development Reference number: GID-QS10105 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Primary hyperparathyroidism

    Awaiting development Reference number: GID-QS10089 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Infant, children and young people's experience of health care

    Awaiting development Reference number: GID-QS10102 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]

    In development Reference number: GID-TA11628 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  12. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    Awaiting development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Filgotinib for treating axial spondyloarthritis ID6594: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 21 January 2026.

    Technology appraisal guidance
    In consultation

  14. Filgotinib for treating axial spondyloarthritis ID6594

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

    Health technology evaluations
    In development